[Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
Manger
B
B
Medinizische Klinik III, Krankenhausstr. 12, 91054 Erlangen.
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D000075202:Contraindications; D019091:Critical Pathways; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D005858:Germany; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D015507:Drugs, Investigational; D014409:Tumor Necrosis Factor-alpha